Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Haleon PLC ( (GB:HLN) ).
Haleon PLC announced the purchase of 2,318,700 ordinary shares as part of its ongoing share buyback program. The shares will be held as treasury shares, impacting the company’s share capital and voting rights. This move is part of Haleon’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £3.80 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Spark’s Take on GB:HLN Stock
According to Spark, TipRanks’ AI Analyst, GB:HLN is a Outperform.
Haleon PLC’s overall stock score reflects a strong financial foundation with robust profitability and cash flow management. However, technical indicators and valuation suggest a more cautious outlook. The earnings call highlighted regional strengths but also significant challenges in North America, impacting the overall sentiment. The absence of notable corporate events leaves the focus on financial and operational performance.
To see Spark’s full report on GB:HLN stock, click here.
More about Haleon PLC
Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with humanity. The company offers a diverse product portfolio across six major categories, including Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. Its well-known brands, such as Advil, Centrum, and Sensodyne, are based on trusted science and innovation.
Average Trading Volume: 20,470,333
Technical Sentiment Signal: Sell
Current Market Cap: £29.46B
Find detailed analytics on HLN stock on TipRanks’ Stock Analysis page.